Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene

Gennady Cherednichenko, Chris W. Ward, Wei Feng, Elaine Cabrales, Luke Michaelson, Montserrat Samso, José R. López, Paul D. Allen, Isaac N Pessah

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Dantrolene is the drug of choice for the treatment of malignant hyperthermia (MH) and is also useful for treatment of spasticity or muscle spasms associated with several clinical conditions. The current study examines the mechanisms of dantrolene's action on skeletal muscle and shows that one of dantrolene's mechanisms of action is to block excitation-coupled calcium entry (ECCE) in both adult mouse flexor digitorum brevis fibers and primary myotubes. A second important new finding is that myotubes isolated from mice heterozygous and homozygous for the ryanodine receptor type 1 R163C MH susceptibility mutation show significantly enhanced ECCE rates that could be restored to those measured in wild-type cells after exposure to clinical concentrations of dantrolene. We propose that this gain of ECCE function is an important etiological component of MH susceptibility and possibly contributes to the fulminant MH episode. The inhibitory potency of dantrolene on ECCE found in wild-type and MH-susceptible muscle is consistent with the drug's clinical potency for reversing the MH syndrome and is incomplete as predicted by its efficacy as a muscle relaxant.

Original languageEnglish (US)
Pages (from-to)1203-1212
Number of pages10
JournalMolecular Pharmacology
Volume73
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Dantrolene
Malignant Hyperthermia
Skeletal Muscle Fibers
Calcium
Mutation
Muscles
Ryanodine Receptor Calcium Release Channel
Spasm
Pharmaceutical Preparations
Skeletal Muscle
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene. / Cherednichenko, Gennady; Ward, Chris W.; Feng, Wei; Cabrales, Elaine; Michaelson, Luke; Samso, Montserrat; López, José R.; Allen, Paul D.; Pessah, Isaac N.

In: Molecular Pharmacology, Vol. 73, No. 4, 04.2008, p. 1203-1212.

Research output: Contribution to journalArticle

Cherednichenko, G, Ward, CW, Feng, W, Cabrales, E, Michaelson, L, Samso, M, López, JR, Allen, PD & Pessah, IN 2008, 'Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene', Molecular Pharmacology, vol. 73, no. 4, pp. 1203-1212. https://doi.org/10.1124/mol.107.043299
Cherednichenko, Gennady ; Ward, Chris W. ; Feng, Wei ; Cabrales, Elaine ; Michaelson, Luke ; Samso, Montserrat ; López, José R. ; Allen, Paul D. ; Pessah, Isaac N. / Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene. In: Molecular Pharmacology. 2008 ; Vol. 73, No. 4. pp. 1203-1212.
@article{07a3dff0a0874ba4ab11d2c12f9d7408,
title = "Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene",
abstract = "Dantrolene is the drug of choice for the treatment of malignant hyperthermia (MH) and is also useful for treatment of spasticity or muscle spasms associated with several clinical conditions. The current study examines the mechanisms of dantrolene's action on skeletal muscle and shows that one of dantrolene's mechanisms of action is to block excitation-coupled calcium entry (ECCE) in both adult mouse flexor digitorum brevis fibers and primary myotubes. A second important new finding is that myotubes isolated from mice heterozygous and homozygous for the ryanodine receptor type 1 R163C MH susceptibility mutation show significantly enhanced ECCE rates that could be restored to those measured in wild-type cells after exposure to clinical concentrations of dantrolene. We propose that this gain of ECCE function is an important etiological component of MH susceptibility and possibly contributes to the fulminant MH episode. The inhibitory potency of dantrolene on ECCE found in wild-type and MH-susceptible muscle is consistent with the drug's clinical potency for reversing the MH syndrome and is incomplete as predicted by its efficacy as a muscle relaxant.",
author = "Gennady Cherednichenko and Ward, {Chris W.} and Wei Feng and Elaine Cabrales and Luke Michaelson and Montserrat Samso and L{\'o}pez, {Jos{\'e} R.} and Allen, {Paul D.} and Pessah, {Isaac N}",
year = "2008",
month = "4",
doi = "10.1124/mol.107.043299",
language = "English (US)",
volume = "73",
pages = "1203--1212",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

TY - JOUR

T1 - Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene

AU - Cherednichenko, Gennady

AU - Ward, Chris W.

AU - Feng, Wei

AU - Cabrales, Elaine

AU - Michaelson, Luke

AU - Samso, Montserrat

AU - López, José R.

AU - Allen, Paul D.

AU - Pessah, Isaac N

PY - 2008/4

Y1 - 2008/4

N2 - Dantrolene is the drug of choice for the treatment of malignant hyperthermia (MH) and is also useful for treatment of spasticity or muscle spasms associated with several clinical conditions. The current study examines the mechanisms of dantrolene's action on skeletal muscle and shows that one of dantrolene's mechanisms of action is to block excitation-coupled calcium entry (ECCE) in both adult mouse flexor digitorum brevis fibers and primary myotubes. A second important new finding is that myotubes isolated from mice heterozygous and homozygous for the ryanodine receptor type 1 R163C MH susceptibility mutation show significantly enhanced ECCE rates that could be restored to those measured in wild-type cells after exposure to clinical concentrations of dantrolene. We propose that this gain of ECCE function is an important etiological component of MH susceptibility and possibly contributes to the fulminant MH episode. The inhibitory potency of dantrolene on ECCE found in wild-type and MH-susceptible muscle is consistent with the drug's clinical potency for reversing the MH syndrome and is incomplete as predicted by its efficacy as a muscle relaxant.

AB - Dantrolene is the drug of choice for the treatment of malignant hyperthermia (MH) and is also useful for treatment of spasticity or muscle spasms associated with several clinical conditions. The current study examines the mechanisms of dantrolene's action on skeletal muscle and shows that one of dantrolene's mechanisms of action is to block excitation-coupled calcium entry (ECCE) in both adult mouse flexor digitorum brevis fibers and primary myotubes. A second important new finding is that myotubes isolated from mice heterozygous and homozygous for the ryanodine receptor type 1 R163C MH susceptibility mutation show significantly enhanced ECCE rates that could be restored to those measured in wild-type cells after exposure to clinical concentrations of dantrolene. We propose that this gain of ECCE function is an important etiological component of MH susceptibility and possibly contributes to the fulminant MH episode. The inhibitory potency of dantrolene on ECCE found in wild-type and MH-susceptible muscle is consistent with the drug's clinical potency for reversing the MH syndrome and is incomplete as predicted by its efficacy as a muscle relaxant.

UR - http://www.scopus.com/inward/record.url?scp=41149098152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149098152&partnerID=8YFLogxK

U2 - 10.1124/mol.107.043299

DO - 10.1124/mol.107.043299

M3 - Article

C2 - 18171728

AN - SCOPUS:41149098152

VL - 73

SP - 1203

EP - 1212

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 4

ER -